A phase 2a trial of the IL-33 mAb tozorakimab in patients with COPD: FRONTIER-4

A phase 2a trial of the IL-33 mAb tozorakimab in patients with COPD: FRONTIER-4

Interleukin-33 may have a role in COPD pathobiology. FRONTIER-4 (NCT04631016) investigated tozorakimab (an anti-IL-33 monoclonal antibody) in moderate-to-severe COPD patients with chronic bronchitis receiving dual or triple inhaled therapy. FRONTIER-4 was a phase 2a, randomized, double-blind, placeb...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Dave Singh, Patricia Guller, Fred Reid, Sarah Doffman, Ulla Seppälä, Ioannis Psallidas, Rachel Moate, Rebecca Smith, Joanna Kiraga, Eulalia Jiménez, Dennis E. Brooks, Aoife Kelly, Lars H. Nordenmark, Muhammad Waqas Sadiq, Luis Mateos Caballero, Chris Kell, Maria G. Belvisi, Hitesh Pandya
Format: Artigo
Idioma:anglès
Publicat: 2025
Accés en línia:https://doi.org/10.1183/13993003.02231-2024
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Internet

https://doi.org/10.1183/13993003.02231-2024

Ítems similars